LMND Form 4: Chief Insurance Officer Receives 25,556-Share Option Grant
Rhea-AI Filing Summary
John Sheldon Peters, Chief Insurance Officer of Lemonade, Inc. (LMND), was granted a stock option covering 25,556 shares with an exercise price of $59.74. The reported transaction date is 08/21/2025 and the Form 4 was filed on 08/25/2025. The option vests in 12 equal quarterly installments beginning 08/18/2025 and becomes exercisable according to that schedule, with an expiration date of 08/18/2035. After this grant, the reporting person directly beneficially owns 25,556 common shares (from this option) at a stated price of $0 for the reported beneficial ownership figure. The form was signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Alignment of interests: Granting of stock options aligns the Chief Insurance Officer's compensation with shareholder value.
- Retention mechanics: Vesting over 12 quarterly installments supports executive retention through 2025–2028 vesting period.
- Timely disclosure: Form 4 was filed within days of the transaction date and signed by an authorized attorney-in-fact.
Negative
- Potential future dilution: The option covers 25,556 shares which will dilute shareholders if exercised.
- No cashless exercise details: The filing does not disclose whether alternative exercise or settlement methods will be available.
Insights
TL;DR: Routine equity compensation grant aligns executive incentives with shareholder value without immediate cash proceeds.
The Form 4 discloses a standard stock option grant of 25,556 shares to the Chief Insurance Officer at a $59.74 exercise price, vesting quarterly over three years starting 08/18/2025 and expiring 08/18/2035. This is a compensation event, not a sale, and does not change outstanding dilution until exercised. For investors, the grant signals continued executive retention incentives but has limited immediate impact on cash flow or share count until exercise.
TL;DR: Standard grant with customary vesting schedule; procedural filing appears complete and timely.
The disclosure identifies the reporting person and relationship (Chief Insurance Officer) and shows the option will vest in 12 equal quarterly installments beginning 08/18/2025. The Form 4 is properly executed by an attorney-in-fact and filed within a few days of the transaction date, consistent with Section 16 reporting practice. There are no indications of accelerated vesting or special terms disclosed here.
FAQ
What did John Peters (LMND) receive according to the Form 4?
When does the option vest and become exercisable?
What is the reporting and filing date on the Form 4 for this transaction?
How many shares does the reporting person beneficially own after the grant?
Who signed the Form 4?